North America Biopharmaceuticals Market Outlook, 2029
The North America Biopharmaceuticals Market is projected to reach a staggering USD 80 billion by 2028, driven by rise in technological advancements.
- Bonafide Trust
- 30-01-2024
- Pages : 153
- Figures : 83
- Tables : 36
- Region : North America
- Category : Lifescience
- Pharmaceutical
According to publisher, Here is the North American Biopharmaceuticals Market is a Prescription for Growth.
The North American Biopharmaceuticals Market is a vital sector, experiencing significant growth due to advancements in biotechnologies and rising demand for innovative treatments. The market size is projected to reach a staggering USD 80 billion by 2028, reflecting a promising CAGR of 8.75%. Here's a concise analysis of this dynamic market:
Market Insights
What's Inside a Bonafide Research`s industry report?
A Bonafide Research industry report provides in-depth market analysis, trends, competitive insights, and strategic recommendations to help businesses make informed decisions.
Download SampleShifting Treatment Landscape: Biopharmaceuticals, unlike traditional small-molecule drugs, target specific biological pathways in diseases, offering a more precise and potentially curative approach. This is driving market growth in areas like oncology and chronic diseases.
Aging Population: The growing elderly population in North America is a key driver. As life expectancy increases, the demand for treatments for age-related diseases like Alzheimer's and cardiovascular conditions is rising.
Market Dynamics
Drivers:
Government Funding for R&D: Government initiatives like the National Institutes of Health (NIH) in the US provide crucial funding for biopharmaceutical research and development, accelerating innovation.
Technological Advancements: Breakthroughs in areas like gene editing and personalized medicine are leading to the development of more targeted and effective biopharmaceuticals.
Restraints:
High Cost of Drug Development: The research, development, and clinical trials required for biopharmaceuticals are expensive, making these drugs potentially less affordable for some patients and healthcare systems.
Stringent Regulatory Requirements: Strict regulations by agencies like the Food and Drug Administration (FDA) ensure safety and efficacy but can also add time and complexity to the drug development process.
Market Segments
Product Type:
Monoclonal Antibodies: These engineered proteins target specific disease-causing molecules, offering promise in treating various cancers and autoimmune diseases. (e.g., Rituximab for lymphoma)
Vaccines: Vaccines continue to be crucial for disease prevention, with ongoing development of novel vaccines addressing emerging infectious diseases. (e.g., mRNA vaccines for COVID-19)
Gene Therapies: These therapies aim to correct genetic defects or introduce therapeutic genes to treat genetic disorders. (e.g., Kymriah for leukemia)
Therapeutic Area:
Oncology: The largest segment due to the high prevalence of cancer and the continuous development of targeted therapies.
Immunology: Focus on treatments for autoimmune diseases and inflammatory conditions.
Metabolic Disorders: Biopharmaceuticals are being developed to manage diabetes and other metabolic conditions.
Regional Analysis
US Dominates: The United States is the undisputed leader due to a well-developed research infrastructure, strong government support, and a large patient population.
Canada's Growing Market: Canada's biopharmaceutical market is experiencing growth, with a focus on research collaborations and attracting clinical trials.
Key Developments
Rise of Biosimilars: Biosimilars are similar to existing biopharmaceuticals but more affordable. Their increasing adoption could improve access to these life-saving treatments.
Precision Medicine: Advancements in personalized medicine allow for tailoring biopharmaceutical treatments to specific patient genotypes for better outcomes.
Focus on Value-Based Care: The healthcare system is shifting towards value-based care, where reimbursement is tied to patient outcomes. This incentivizes biopharmaceutical companies to develop drugs with demonstrably better health benefits.
Competitive Landscape
Big Pharma and Emerging Players: Major pharmaceutical companies (e.g., Pfizer, Amgen) dominate the market, but smaller biotech firms are emerging with innovative biopharmaceutical candidates.
Strategic Collaborations: Partnerships between large pharmaceutical companies and biotech startups are becoming increasingly common to leverage complementary expertise and accelerate drug development.
Future Outlook
The North American Biopharmaceuticals Market is brimming with potential, driven by:
Continued R&D investments
Technological breakthroughs in bioengineering
Focus on personalized and affordable treatments
This will lead to the development of a wider range of biopharmaceuticals for various diseases, potentially transforming healthcare and improving patient outcomes. However, managing high development costs and navigating regulatory hurdles will remain crucial challenges for the industry.
Table of Contents
- 1 Introduction 9
- 1.1 Industry Definition and Research Scope 9
- 1.1.1 Industry Definition 9
- 1.1.2 Research Scope 10
- 1.2 Research Methodology 13
- 1.2.1 Overview of Market Research Methodology 13
- 1.2.2 Market Assumption 14
- 1.2.3 Secondary Data 14
- 1.2.4 Primary Data 14
- 1.2.5 Data Filtration and Model Design 15
- 1.2.6 Market Size/Share Estimation 16
- 1.2.7 Research Limitations 17
- 1.3 Executive Summary 18
- 2 Market Overview and Dynamics 21
- 2.1 Market Size and Forecast 21
- 2.1.1 Impact of COVID-19 on World Economy 22
- 2.1.2 Impact of COVID-19 on the Market 26
- 2.1.3 Impact of Russia-Ukraine Conflict 28
- 2.1.4 Impact of Israel-Palestine War 30
- 2.2 Major Growth Drivers 31
- 2.3 Market Restraints and Challenges 40
- 2.4 Emerging Opportunities and Market Trends 43
- 2.5 Porter’s Fiver Forces Analysis 47
- 3 Segmentation of North America Market by Product Type 51
- 3.1 Market Overview by Product Type 51
- 3.2 Monoclonal Antibodies 53
- 3.2.1 Anti-cancer Monoclonal Antibodies 54
- 3.2.2 Anti-inflammatory Monoclonal Antibodies 55
- 3.2.3 Other Monoclonal Antibodies 56
- 3.3 Recombinant Growth Factors 57
- 3.3.1 Erythropoietin 58
- 3.3.2 Granulocyte Colony Stimulating Factor 59
- 3.4 Purified Proteins 60
- 3.4.1 Leukemia Inhibitory Factor (LIF) 61
- 3.4.2 P53 Protein 62
- 3.4.3 P38 Protein 63
- 3.4.4 Other Purified Proteins 64
- 3.5 Recombinant Proteins 65
- 3.5.1 Serum Albumin 66
- 3.5.2 Amyloid Protein 67
- 3.5.3 Defensin 68
- 3.5.4 Transferrin 69
- 3.6 Recombinant Hormones 70
- 3.6.1 Recombinant Human Growth Hormones 71
- 3.6.2 Recombinant Insulin 73
- 3.6.3 Other Recombinant Hormones 74
- 3.7 Vaccines 75
- 3.7.1 Recombinant Vaccines 76
- 3.7.2 Conventional Vaccines 78
- 3.8 Recombinant Enzymes 79
- 3.8.1 Enterokinase 80
- 3.8.2 Cyclase 81
- 3.8.3 Caspase 82
- 3.8.4 Cathepsin 83
- 3.9 Cell and Gene Therapies 84
- 3.9.1 Allogenic Products 85
- 3.9.2 Autologous Products 86
- 3.9.3 Acellular Products 87
- 3.10 Synthetic Immunomodulators 88
- 3.11 Other Product Types 89
- 3.11.1 Blood Factors 90
- 3.11.2 Other Products 91
- 4 Segmentation of North America Market by Testing Service 92
- 4.1 Market Overview by Testing Service 92
- 4.2 Laboratory Testing 94
- 4.3 Custom Testing/Customer Proprietary Testing 95
- 4.4 Compendial and Multi Compendial Laboratory Testing 96
- 5 Segmentation of North America Market by Raw Material 97
- 5.1 Market Overview by Raw Material 97
- 5.2 Formulation Excipients 99
- 5.3 Active Pharmaceutical Ingredients (API) 100
- 5.4 Other Materials 101
- 6 Segmentation of North America Market by Classification 102
- 6.1 Market Overview by Classification 102
- 6.2 Innovative Biopharmaceuticals 104
- 6.3 Biogenerics and Biosimilars 105
- 7 Segmentation of North America Market by Therapeutic Area 106
- 7.1 Market Overview by Therapeutic Area 106
- 7.2 Oncology 108
- 7.3 Inflammatory and Infectious Diseases 109
- 7.4 Autoimmune Disorders 110
- 7.5 Metabolic Disorders 111
- 7.6 Hormonal Disorders 112
- 7.7 Cardiovascular Diseases 113
- 7.8 Neurological Diseases 114
- 7.9 Other Therapeutic Areas 115
- 8 North America Market 2023-2033 by Country 116
- 8.1 Overview of North America Market 116
- 8.2 U.S. 119
- 8.3 Canada 122
- 8.4 Mexico 124
- 9 Competitive Landscape 126
- 9.1 Overview of Key Vendors 126
- 9.2 New Product Launch, Partnership, Investment, and M&A 130
- 9.3 Company Profiles 131
- Abbott Laboratories 131
- Amgen Inc. 133
- Astrazeneca PLC 134
- Bayer AG 135
- Biogen Inc. 136
- Bristol-myers Squibb Company (BMS) 137
- Eli Lilly and Company 138
- F. Hoffmann-La Roche Ltd. 139
- Glaxosmithkline PLC 140
- Johnson & Johnson 141
- Merck & Co. Inc. 142
- Novartis Ag 143
- Novo Nordisk As 144
- Pfizer Inc. 145
- Sanofi Sa 146
- Sharp Packaging Services 147
- Sun Pharmaceutical Industries Ltd. 148
- Takeda Pharmaceutical Company Limited 149
- Thermo Fisher Scientific Inc. 150
- Vertex Pharmaceuticals 151
- WuXi AppTec 152
- RELATED REPORTS 153
Table 1. Snapshot of North America Biopharmaceuticals Market in Balanced Perspective, 2023-2033 19
Table 2. World Economic Outlook, 2024-2036 23
Table 3. World Economic Outlook, 2022-2024 25
Table 4. Scenarios for Economic Impact of Ukraine Crisis 29
Table 5. Scenarios for Economic Impact of Israel-Palestine War 30
Table 6. World Health Spending by Region, $ bn, 2013-2020 35
Table 7. Total Number of Registered Clinical Studies Worldwide, 2010-2021 36
Table 8. Worldwide Number of New Cancer by Type, 2020 37
Table 9. Main Product Trends and Market Opportunities in North America Biopharmaceuticals Market 43
Table 10. North America Biopharmaceuticals Market by Product Type, 2023-2033, $ mn 51
Table 11. North America Biopharmaceuticals Market: Monoclonal Antibodies by Type, 2023-2033, $ mn 53
Table 12. North America Biopharmaceuticals Market: Recombinant Growth Factor by Type, 2023-2033, $ mn 57
Table 13. North America Biopharmaceuticals Market: Purified Proteins by Type, 2023-2033, $ mn 60
Table 14. North America Biopharmaceuticals Market: Recombinant Proteins by Type, 2023-2033, $ mn 65
Table 15. North America Biopharmaceuticals Market: Recombinant Hormones by Type, 2023-2033, $ mn 70
Table 16. Selected Drugs for COVID-19 Treatment in Development, Nov 2022 72
Table 17. North America Biopharmaceuticals Market: Vaccines by Type, 2023-2033, $ mn 75
Table 18. North America Biopharmaceuticals Market: Recombinant Vaccines by Type, 2023-2033, $ mn 77
Table 19. North America Biopharmaceuticals Market: Conventional Vaccines by Type, 2023-2033, $ mn 78
Table 20. North America Biopharmaceuticals Market: Recombinant Enzymes by Type, 2023-2033, $ mn 79
Table 21. North America Biopharmaceuticals Market: Cell and Gene Therapies by Type, 2023-2033, $ mn 84
Table 22. North America Biopharmaceuticals Market: Other Product Types by Type, 2023-2033, $ mn 89
Table 23. North America Biopharmaceuticals Market by Testing Service, 2023-2033, $ mn 92
Table 24. North America Biopharmaceuticals Market by Raw Material, 2023-2033, $ mn 97
Table 25. North America Biopharmaceuticals Market by Classification, 2023-2033, $ mn 102
Table 26. North America Biopharmaceuticals Market by Therapeutic Area, 2023-2033, $ mn 106
Table 27. North America Biopharmaceuticals Market by Country, 2023-2033, $ mn 117
Table 28. U.S. Biopharmaceuticals Market by Product Type, 2023-2033, $ mn 121
Table 29. U.S. Biopharmaceuticals Market by Therapeutic Area, 2023-2033, $ mn 121
Table 30. Canada Biopharmaceuticals Market by Product Type, 2023-2033, $ mn 123
Table 31. Canada Biopharmaceuticals Market by Therapeutic Area, 2023-2033, $ mn 123
Table 32. Mexico Biopharmaceuticals Market by Product Type, 2023-2033, $ mn 125
Table 33. Mexico Biopharmaceuticals Market by Therapeutic Area, 2023-2033, $ mn 125
Table 34. Abbott Laboratories: Company Snapshot 131
Table 35. Abbott Laboratories: Business Segmentation 132
Table 36. Abbott Laboratories: Product Portfolio 132
Figure 1. Research Method Flow Chart 13
Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation 16
Figure 3. North America Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2023-2033 18
Figure 4. North America Biopharmaceuticals Market, 2023-2033, $ mn 21
Figure 5. Impact of COVID-19 on Business 26
Figure 6. Primary Drivers and Impact Factors of North America Biopharmaceuticals Market 31
Figure 7. Worldwide Geriatric Population (60 years and above) by Regions, 2015 & 2030, million 34
Figure 8. World Population 65 and Over, % of Total Population, 1950-2060 34
Figure 9. Worldwide Novel Active Substances (NASs) Launches by Therapeutic Area, 2013-2022 35
Figure 10. Primary Restraints and Impact Factors of North America Biopharmaceuticals Market 40
Figure 11. Investment Opportunity Analysis 44
Figure 12. Porter’s Fiver Forces Analysis of North America Biopharmaceuticals Market 47
Figure 13. Breakdown of North America Biopharmaceuticals Market by Product Type, 2023-2033, % of Revenue 52
Figure 14. North America Addressable Market Cap in 2024-2033 by Product Type, Value ($ mn) and Share (%) 52
Figure 15. North America Biopharmaceuticals Market by Product Type: Monoclonal Antibodies, 2023-2033, $ mn 53
Figure 16. North America Biopharmaceuticals Market by Monoclonal Antibodies: Anti-cancer Monoclonal Antibodies, 2023-2033, $ mn 54
Figure 17. North America Biopharmaceuticals Market by Monoclonal Antibodies: Anti-inflammatory Monoclonal Antibodies, 2023-2033, $ mn 55
Figure 18. North America Biopharmaceuticals Market by Monoclonal Antibodies: Other Monoclonal Antibodies, 2023-2033, $ mn 56
Figure 19. North America Biopharmaceuticals Market by Product Type: Recombinant Growth Factors, 2023-2033, $ mn 57
Figure 20. North America Biopharmaceuticals Market by Recombinant Growth Factor: Erythropoietin, 2023-2033, $ mn 58
Figure 21. North America Biopharmaceuticals Market by Recombinant Growth Factor: Granulocyte Colony Stimulating Factor, 2023-2033, $ mn 59
Figure 22. North America Biopharmaceuticals Market by Product Type: Purified Proteins, 2023-2033, $ mn 60
Figure 23. North America Biopharmaceuticals Market by Purified Proteins: Leukemia Inhibitory Factor (LIF), 2023-2033, $ mn 61
Figure 24. North America Biopharmaceuticals Market by Purified Proteins: P53 Protein, 2023-2033, $ mn 62
Figure 25. North America Biopharmaceuticals Market by Purified Proteins: P38 Protein, 2023-2033, $ mn 63
Figure 26. North America Biopharmaceuticals Market by Purified Proteins: Other Purified Proteins, 2023-2033, $ mn 64
Figure 27. North America Biopharmaceuticals Market by Product Type: Recombinant Proteins, 2023-2033, $ mn 65
Figure 28. North America Biopharmaceuticals Market by Recombinant Proteins: Serum Albumin, 2023-2033, $ mn 66
Figure 29. North America Biopharmaceuticals Market by Recombinant Proteins: Amyloid Protein, 2023-2033, $ mn 67
Figure 30. North America Biopharmaceuticals Market by Recombinant Proteins: Defensin, 2023-2033, $ mn 68
Figure 31. North America Biopharmaceuticals Market by Recombinant Proteins: Transferrin, 2023-2033, $ mn 69
Figure 32. North America Biopharmaceuticals Market by Product Type: Recombinant Hormones, 2023-2033, $ mn 70
Figure 33. North America Biopharmaceuticals Market by Recombinant Hormones: Recombinant Human Growth Hormones, 2023-2033, $ mn 71
Figure 34. North America Biopharmaceuticals Market by Recombinant Hormones: Recombinant Insulin, 2023-2033, $ mn 73
Figure 35. North America Biopharmaceuticals Market by Recombinant Hormones: Other Recombinant Hormones, 2023-2033, $ mn 74
Figure 36. North America Biopharmaceuticals Market by Product Type: Vaccines, 2023-2033, $ mn 75
Figure 37. North America Biopharmaceuticals Market by Vaccines: Recombinant Vaccines, 2023-2033, $ mn 76
Figure 38. North America Biopharmaceuticals Market by Vaccines: Conventional Vaccines, 2023-2033, $ mn 78
Figure 39. North America Biopharmaceuticals Market by Product Type: Recombinant Enzymes, 2023-2033, $ mn 79
Figure 40. North America Biopharmaceuticals Market by Recombinant Enzymes: Enterokinase, 2023-2033, $ mn 80
Figure 41. North America Biopharmaceuticals Market by Recombinant Enzymes: Cyclase, 2023-2033, $ mn 81
Figure 42. North America Biopharmaceuticals Market by Recombinant Enzymes: Caspase, 2023-2033, $ mn 82
Figure 43. North America Biopharmaceuticals Market by Recombinant Enzymes: Cathepsin, 2023-2033, $ mn 83
Figure 44. North America Biopharmaceuticals Market by Product Type: Cell and Gene Therapies, 2023-2033, $ mn 84
Figure 45. North America Biopharmaceuticals Market by Cell and Gene Therapies: Allogenic Products, 2023-2033, $ mn 85
Figure 46. North America Biopharmaceuticals Market by Cell and Gene Therapies: Autologous Products, 2023-2033, $ mn 86
Figure 47. North America Biopharmaceuticals Market by Cell and Gene Therapies: Acellular Products, 2023-2033, $ mn 87
Figure 48. North America Biopharmaceuticals Market by Product Type: Synthetic Immunomodulators, 2023-2033, $ mn 88
Figure 49. North America Biopharmaceuticals Market by Product Type: Other Product Types, 2023-2033, $ mn 89
Figure 50. North America Biopharmaceuticals Market by Other Product Types: Blood Factors, 2023-2033, $ mn 90
Figure 51. North America Biopharmaceuticals Market by Other Product Types: Other Products, 2023-2033, $ mn 91
Figure 52. Breakdown of North America Biopharmaceuticals Market by Testing Service, 2023-2033, % of Sales Revenue 93
Figure 53. North America Addressable Market Cap in 2024-2033 by Testing Service, Value ($ mn) and Share (%) 93
Figure 54. North America Biopharmaceuticals Market by Testing Service: Laboratory Testing, 2023-2033, $ mn 94
Figure 55. North America Biopharmaceuticals Market by Testing Service: Custom Testing/Customer Proprietary Testing, 2023-2033, $ mn 95
Figure 56. North America Biopharmaceuticals Market by Testing Service: Compendial and Multi Compendial Laboratory Testing, 2023-2033, $ mn 96
Figure 57. Breakdown of North America Biopharmaceuticals Market by Raw Material, 2023-2033, % of Sales Revenue 98
Figure 58. North America Addressable Market Cap in 2024-2033 by Raw Material, Value ($ mn) and Share (%) 98
Figure 59. North America Biopharmaceuticals Market by Raw Material: Formulation Excipients, 2023-2033, $ mn 99
Figure 60. North America Biopharmaceuticals Market by Raw Material: Active Pharmaceutical Ingredients (API), 2023-2033, $ mn 100
Figure 61. North America Biopharmaceuticals Market by Raw Material: Other Materials, 2023-2033, $ mn 101
Figure 62. Breakdown of North America Biopharmaceuticals Market by Classification, 2023-2033, % of Revenue 103
Figure 63. North America Addressable Market Cap in 2024-2033 by Classification, Value ($ mn) and Share (%) 103
Figure 64. North America Biopharmaceuticals Market by Classification: Innovative Biopharmaceuticals, 2023-2033, $ mn 104
Figure 65. North America Biopharmaceuticals Market by Classification: Biogenerics and Biosimilars, 2023-2033, $ mn 105
Figure 66. Breakdown of North America Biopharmaceuticals Market by Therapeutic Area, 2023-2033, % of Revenue 107
Figure 67. North America Addressable Market Cap in 2024-2033 by Therapeutic Area, Value ($ mn) and Share (%) 107
Figure 68. North America Biopharmaceuticals Market by Therapeutic Area: Oncology, 2023-2033, $ mn 108
Figure 69. North America Biopharmaceuticals Market by Therapeutic Area: Inflammatory and Infectious Diseases, 2023-2033, $ mn 109
Figure 70. North America Biopharmaceuticals Market by Therapeutic Area: Autoimmune Disorders, 2023-2033, $ mn 110
Figure 71. North America Biopharmaceuticals Market by Therapeutic Area: Metabolic Disorders, 2023-2033, $ mn 111
Figure 72. North America Biopharmaceuticals Market by Therapeutic Area: Hormonal Disorders, 2023-2033, $ mn 112
Figure 73. North America Biopharmaceuticals Market by Therapeutic Area: Cardiovascular Diseases, 2023-2033, $ mn 113
Figure 74. North America Biopharmaceuticals Market by Therapeutic Area: Neurological Diseases, 2023-2033, $ mn 114
Figure 75. North America Biopharmaceuticals Market by Therapeutic Area: Other Therapeutic Areas, 2023-2033, $ mn 115
Figure 76. Breakdown of North America Biopharmaceuticals Market by Country, 2023 and 2033, % of Revenue 117
Figure 77. Contribution to North America 2024-2033 Cumulative Market by Country, Value ($ mn) and Share (%) 118
Figure 78. U.S. Biopharmaceuticals Market, 2023-2033, $ mn 120
Figure 79. Venture Capital Deal Activity and Investment Flows in the U.S., 2013-2022, $ bn and Deal Counts 120
Figure 80. Canada Biopharmaceuticals Market, 2023-2033, $ mn 122
Figure 81. Biopharmaceuticals Market in Mexico, 2023-2033, $ mn 124
Figure 82. Growth Stage of North America Biopharmaceuticals Industry over the Forecast Period 126
Figure 83. Worldwide Top Ten Best-selling Biotech Drugs in 2022, $ bn 128
Related Reports
One individual can access, store, display, or archive the report in Excel format but cannot print, copy, or share it. Use is confidential and internal only. Read More
One individual can access, store, display, or archive the report in PDF format but cannot print, copy, or share it. Use is confidential and internal only. Read More
Up to 10 employees in one region can store, display, duplicate, and archive the report for internal use. Use is confidential and printable. Read More
All employees globally can access, print, copy, and cite data externally (with attribution to Bonafide Research). Read More
Safe and Secure SSL Encrypted
Quick Contacts
Want to customize this report?
We offer 10% Free Customization at the time of purchase
Get Free Customization.png "Nikita Jabrela")
Trusted Partners
Budget constraints? Get in touch with us for special pricing
Request DiscountOrder Detail
- Order Placed (15 March, 2025)
- Notify To Team (15 March, 2025)
- Report updation (16 March, 2025)
- Report Quality Check (16 March, 2025)
- Report Dispatch (17 March, 2025)
- Hard Copy
Recently Viewed Products
North America Biopharmaceuticals Market Outlook, 2029
We are friendly and approachable, give us a call.